Combined with our findings and previous research results, we can speculate that the unsatisfactory therapeutic effects of delayed neuroprotectant administration in ischemic stroke patients, within the short time window for effective treatment may be related to the loss of βCR expression in the early stages of stroke. This evidence concerns the gene BCR and ischemic stroke.